Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) FCF Margin (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed FCF Margin for 6 consecutive years, with 378.46% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin fell 34861.0% to 378.46% in Q3 2025 year-over-year; TTM through Sep 2025 was 156.97%, a 3620.0% increase, with the full-year FY2024 number at 144.0%, up 33929.0% from a year prior.
  • FCF Margin was 378.46% for Q3 2025 at Ensysce Biosciences, down from 197.37% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 29.77% in Q2 2021 to a low of 2403.54% in Q3 2022.
  • A 5-year average of 593.05% and a median of 349.86% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -211053bps in 2022, then skyrocketed 188385bps in 2023.
  • Ensysce Biosciences' FCF Margin stood at 230.41% in 2021, then grew by 0bps to 229.91% in 2022, then crashed by -52bps to 349.86% in 2023, then surged by 83bps to 58.61% in 2024, then plummeted by -546bps to 378.46% in 2025.
  • Per Business Quant, the three most recent readings for ENSC's FCF Margin are 378.46% (Q3 2025), 197.37% (Q2 2025), and 129.37% (Q1 2025).